AbbVie Inc. $ABBV Stock Position Boosted by Nippon Life Global Investors Americas Inc.

Posted by Brenda Bartman on Nov 2nd, 2026

Nippon Life Global Investors Americas Inc. raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 42.5% in the third quarter, Holdings Channel reports. The firm owned 59,950 shares of the company’s stock after acquiring an additional 17,870 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in AbbVie were worth $15,682,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Verus Financial Partners Inc. boosted its stake in AbbVie by 1.7% during the 3rd quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after purchasing an additional 35 shares during the last quarter. Lifelong Wealth Advisors Inc. increased its holdings in shares of AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after purchasing an additional 36 shares in the last quarter. IMG Wealth Management Inc. lifted its holdings in shares of AbbVie by 22.8% during the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after purchasing an additional 36 shares in the last quarter. Foundry Financial Group Inc. boosted its position in shares of AbbVie by 4.6% during the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after buying an additional 37 shares during the last quarter. Finally, DecisionMap Wealth Management LLC boosted its position in shares of AbbVie by 3.2% during the third quarter. DecisionMap Wealth Management LLC now owns 1,207 shares of the company’s stock valued at $316,000 after buying an additional 37 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ABBV. Leerink Partners lifted their price objective on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Guggenheim restated a “buy” rating and set a $288.00 target price on shares of AbbVie in a research note on Friday, October 9th. BNP Paribas Exane raised their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. Finally, Piper Sandler increased their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $282.00.

Read Our Latest Stock Analysis on AbbVie

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Stock Performance

AbbVie stock opened at $294.80 on Monday. The stock has a market cap of $520.85 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. AbbVie Inc. has a one year low of $190.75 and a one year high of $298.74. The stock has a fifty day moving average of $269.35 and a 200 day moving average of $237.23.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.86 earnings per share. As a group, sell-side analysts predict that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s payout ratio is 119.10%.

About AbbVie

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.